Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
EMVision Medical Devices is an Australian pre-revenue medical device company developing portable electromagnetic brain imaging technology for stroke detection and monitoring. The company is in clinical development stage with its EMV100 device, targeting emergency departments and ambulances for rapid stroke triage. As a development-stage biotech, the stock trades on clinical milestone achievement and capital runway rather than operational fundamentals.
EMVision is developing electromagnetic imaging technology as a portable, radiation-free alternative to CT scans for stroke detection. The business model targets hospital emergency departments and ambulance services where rapid stroke triage is critical. Revenue generation depends on regulatory approval (TGA in Australia, FDA in US, CE Mark in Europe), followed by commercialization through direct sales or distribution partnerships. Pricing power will depend on demonstrating clinical utility, cost-effectiveness versus CT/MRI, and reimbursement pathway establishment. Current operations are funded through equity raises with no commercial revenue.
Clinical trial results and regulatory milestone announcements for EMV100 device (TGA, FDA, CE Mark submissions and approvals)
Capital raising announcements and cash runway updates - critical given 4.90x current ratio and ongoing burn rate
Strategic partnerships or licensing agreements with established medical device companies for distribution
Peer company developments in stroke detection technology or competitive imaging modalities
Healthcare reimbursement policy changes affecting diagnostic imaging in emergency settings
Regulatory approval risk - EMV100 must demonstrate clinical efficacy and safety versus established CT/MRI standards across multiple jurisdictions (TGA, FDA, CE Mark), with uncertain timelines and binary outcomes
Reimbursement pathway uncertainty - even with regulatory approval, achieving favorable reimbursement codes and rates from Medicare, private insurers, and international payers is critical for commercial viability
Technology obsolescence risk - competing stroke detection technologies (portable CT, AI-enhanced imaging, biomarker tests) could render electromagnetic imaging approach non-competitive before commercialization
Established imaging modalities (CT, MRI) have entrenched hospital workflows, radiologist familiarity, and proven clinical pathways - high switching costs and physician adoption barriers
Well-capitalized competitors in portable imaging (GE Healthcare, Siemens Healthineers, Philips) could develop competing portable stroke detection solutions with superior distribution and brand recognition
Alternative stroke triage approaches (blood biomarkers, AI-based clinical decision tools) may achieve faster regulatory approval and market penetration at lower cost points
Capital runway risk - with AUD 7-8M annual burn rate and pre-revenue status, company faces recurring dilution risk from equity raises every 12-18 months until commercialization
Debt/equity of 0.38 suggests some leverage, unusual for pre-revenue biotech - potential convertible notes or equipment financing that could create near-term cash obligations or dilution triggers
Negative 79.4% ROE and 65.5% ROA reflect ongoing losses - requires sustained capital access to reach commercialization, with no guarantee of profitability even post-approval
low - As a pre-revenue clinical-stage company, EMVision is largely insulated from economic cycles. Stock performance is driven by binary clinical/regulatory events rather than GDP or consumer spending. However, hospital capital equipment budgets can be affected by healthcare system financial stress during recessions, which could impact future commercialization timing.
Rising interest rates negatively impact EMVision through multiple channels: (1) higher discount rates compress NPV of future cash flows, particularly punitive for long-duration development assets; (2) risk-free rate competition makes speculative biotech less attractive versus bonds; (3) potential difficulty raising capital at attractive valuations in higher-rate environments. With 16.2x price/book and negative cash flow, valuation is highly sensitive to cost of capital assumptions.
Minimal direct credit exposure given pre-revenue status and no debt-dependent business model. However, access to equity capital markets is critical for funding operations. Credit market stress or risk-off sentiment can severely constrain ability to raise capital, creating existential risk given negative operating cash flow of AUD 7-8M annually.
growth - Attracts speculative biotech investors focused on binary clinical/regulatory catalysts with asymmetric risk/reward profiles. Typical holders include specialized healthcare funds, retail investors seeking high-risk/high-reward opportunities, and Australian small-cap growth funds. Not suitable for value or income investors given pre-revenue status, negative cash flow, and absence of dividends. Requires high risk tolerance and long investment horizon (3-5+ years to potential commercialization).
high - Pre-revenue medical device stocks exhibit extreme volatility around clinical data releases, regulatory decisions, and capital raising events. Small market cap (AUD 200M) and likely low trading liquidity amplify price swings. Stock can move 20-50% on single announcements. Beta likely exceeds 1.5-2.0 versus broader market given speculative nature and binary event risk.